Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 8 5 versus TRAVASOL 5 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 8 5 versus TRAVASOL 5 5 W ELECTROLYTES.
AMINOSYN II 8.5% vs TRAVASOL 5.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis when administered intravenously. It serves as a substrate for protein metabolism, promoting nitrogen retention and tissue repair.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
Intravenous infusion, typical adult dose is 1.0 to 1.5 g amino acids/kg/day, administered as part of total parenteral nutrition; rate not to exceed 0.1 g amino acids/kg/hour.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
None Documented
None Documented
Variable; individual amino acids have half-lives ranging from minutes to hours. Clinical context: infusion rate and metabolic demand determine steady-state levels.
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Amino acids are primarily eliminated via metabolism; less than 10% is excreted renally as free amino acids. No significant biliary or fecal excretion.
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution